Ludovic Evesque

2.8k total citations · 2 hit papers
57 papers, 1.1k citations indexed

About

Ludovic Evesque is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ludovic Evesque has authored 57 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 29 papers in Surgery. Recurrent topics in Ludovic Evesque's work include Colorectal Cancer Treatments and Studies (21 papers), Colorectal and Anal Carcinomas (19 papers) and Gastric Cancer Management and Outcomes (19 papers). Ludovic Evesque is often cited by papers focused on Colorectal Cancer Treatments and Studies (21 papers), Colorectal and Anal Carcinomas (19 papers) and Gastric Cancer Management and Outcomes (19 papers). Ludovic Evesque collaborates with scholars based in France, United States and United Kingdom. Ludovic Evesque's co-authors include Min‐Hee Ryu, Lucjan Wyrwicz, Michael Schenker, Narikazu Boku, Julien Taı̈eb, Ilaria Conti, Se Hoon Park, Hua Xiong, María Alsina and Janet Hong and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Oncology.

In The Last Decade

Ludovic Evesque

46 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

2018 372 citations Ludovic Evesque, Markus Moehler et al. Annals of Oncology profile →
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

2024 57 citations Thierry Conroy, Florence Castan et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ludovic Evesque France	14	648	449	447	203	155	57	1.1k
Katharina Biermann Netherlands	19	787 1.2×	841 1.9×	726 1.6×	102 0.5×	55 0.4×	61	1.5k
Joris I. Erdmann Netherlands	17	670 1.0×	456 1.0×	590 1.3×	193 1.0×	24 0.2×	85	1.1k
Shefali Agrawal United States	14	351 0.5×	183 0.4×	337 0.8×	153 0.8×	80 0.5×	29	807
Jan–Werner Poley Netherlands	8	928 1.4×	334 0.7×	631 1.4×	179 0.9×	108 0.7×	9	1.1k
Do Hyoung Lim South Korea	15	725 1.1×	642 1.4×	365 0.8×	75 0.4×	198 1.3×	39	1.1k
A. Azzedine France	6	733 1.1×	422 0.9×	228 0.5×	213 1.0×	85 0.5×	8	972
Isabelle Trouilloud France	13	522 0.8×	269 0.6×	248 0.6×	205 1.0×	17 0.1×	39	689
Kevin Monahan United Kingdom	14	1.1k 1.6×	356 0.8×	661 1.5×	287 1.4×	54 0.3×	67	1.4k
Yoo‐Joung Ko Canada	14	543 0.8×	269 0.6×	237 0.5×	117 0.6×	18 0.1×	43	734
A. Wein Germany	16	485 0.7×	260 0.6×	309 0.7×	64 0.3×	33 0.2×	43	777

Countries citing papers authored by Ludovic Evesque

Since Specialization

Citations

This map shows the geographic impact of Ludovic Evesque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ludovic Evesque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ludovic Evesque more than expected).

Fields of papers citing papers by Ludovic Evesque

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ludovic Evesque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ludovic Evesque. The network helps show where Ludovic Evesque may publish in the future.

Co-authorship network of co-authors of Ludovic Evesque

This figure shows the co-authorship network connecting the top 25 collaborators of Ludovic Evesque. A scholar is included among the top collaborators of Ludovic Evesque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ludovic Evesque. Ludovic Evesque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ducreux, Michel, Yves Rinaldi, Frédéric Di Fiore, et al.. (2025). PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. Journal of Clinical Oncology. 43(20). 2255–2264. 3 indexed citations

Mitrea, Diana M., N. Barbet, D. Baron, et al.. (2024). ‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study. Cancer/Radiothérapie. 28(4). 323–332. 1 indexed citations

Adenis, Antoine, François Ghiringhelli, Thibault Mazard, et al.. (2024). Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemotherapy and Pharmacology. 94(3). 443–452. 1 indexed citations

Moehler, Markus, D-Y. Oh, Kazuyoshi Kato, et al.. (2024). 397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305. Annals of Oncology. 35. S160–S161. 7 indexed citations

Conroy, Thierry, Florence Castan, Pierre-Luc Etienne, et al.. (2024). Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Annals of Oncology. 35(10). 873–881. 57 indexed citations breakdown →

Baron, D., Renaud Schiappa, N. Barbet, et al.. (2024). A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. Annals of Oncology. 36(2). 208–215. 5 indexed citations

Bailleux, Caroline, C. Zwarthoed, Ludovic Evesque, et al.. (2023). Prognostic impact of post-treatment FDG PET/CT in anal canal cancer: A prospective study. Radiotherapy and Oncology. 188. 109905–109905.

Piquemal, David, Florian Noguier, Barbara Bournet, et al.. (2023). SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer. Annals of Oncology. 34. S164–S165.

Boccaccino, Alessandra, Claire Gallois, Maria Antista, et al.. (2022). Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series. European Journal of Cancer. 168. 34–40. 8 indexed citations

10.

Schiappa, Renaud, et al.. (2022). Failure of Initial Curative Treatment for Non-Metastatic Anal Squamous Cell Carcinoma: From Prognostic Factors Analysis to Stratified Treatment. Clinical Colorectal Cancer. 21(4). 362–370.

11.

Tougeron, David, Farid El Hajbi, Karine Le Malicot, et al.. (2022). 1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. Annals of Oncology. 33. S1099–S1100. 1 indexed citations

12.

Neuzillet, Cindy, Andrea Casadei‐Gardini, Bertrand Brieau, et al.. (2020). Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer. 147(11). 3177–3188. 17 indexed citations

13.

Kinj, Rémy, J. Doyen, Jean‐Michel Hannoun‐Lévi, et al.. (2020). Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse. Clinical Oncology. 33(1). e15–e21. 4 indexed citations

14.

Evesque, Ludovic, et al.. (2020). Les carcinomes épidermoïdes métastatiques du canal anal : prise en charge actuelle et perspectives. Bulletin du Cancer. 107(7-8). 792–799. 1 indexed citations

15.

Borchiellini, Delphine, Benjamin Hoch, Vittoria Raimondi, et al.. (2019). Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study. Supportive Care in Cancer. 28(4). 1639–1647. 10 indexed citations

16.

Samalin, Emmanuelle, Anthony Turpin, Faïza Khemissa, et al.. (2019). Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI). Annals of Oncology. 30. iv21–iv21. 2 indexed citations

17.

Bénézery, Karen, D. Lam Cham Kee, Éric François, et al.. (2018). Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal. Journal of Contemporary Brachytherapy. 10(6). 522–531. 3 indexed citations

18.

Follana, Philippe, et al.. (2016). Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX. Oncology. 90(5). 261–266. 18 indexed citations

19.

Novellas, S., et al.. (2012). Placement of metallic biliary endoprostheses in complex hilar tumours. Diagnostic and Interventional Imaging. 93(10). 767–774. 3 indexed citations

20.

Oussalah, Abderrahim, Ludovic Evesque, David Laharie, et al.. (2010). A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. The American Journal of Gastroenterology. 105(12). 2617–2625. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact